Predict your next investment

HEALTHCARE | Pharmaceutical Distribution & Wholesale
makingmedicinesbetter.com

See what CB Insights has to offer

About TLC Therapeutics

TLC Therapeutics is a pharmaceutical company focused on identifying and commercializing pharmaceutical products with dosage forms that address unmet needs.

TLC Therapeutics Headquarter Location

Baltimore, Maryland,

United States

Latest TLC Therapeutics News

Novaliq GmbH Announces Licensing Agreement with AFT Pharmaceuticals for the Distribution of NovaTearsÂ

Mar 20, 2017

TLC Therapeutics, LLC Announces Multi-Product Licensing And Manufacturing Agreement With Rosemont Pharmaceuticals Ltd. Novaliq, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced a strategic licensing agreement with AFT Pharmaceuticals (AFT) for the commercialization of Novaliq’s lead product NovaTears® in Australia and New Zealand. NovaTears is Novaliq’s first commercially available ophthalmic product for the treatment of evaporative dry eye diseases (DEDs). In Europe, NovaTears is distributed by URSAPHARM under the brand name EvoTears®. Under the terms of the agreement, Novaliq has granted AFT an exclusive license for the commercialization of NovaTears across Australasia. In return for these rights, Novaliq will receive an undisclosed upfront payment and royalties on net sales of NovaTears. “Novaliq is delighted to collaborate with AFT, a leading and innovative pharmaceutical company with a strong commitment to eye care,” said Christian Roesky, PhD, CEO, Novaliq. “NovaTears provides a highly differentiated and clinically validated treatment option that significantly improves the signs and symptoms of evaporative DED and Meibomian gland dysfunction (MGD), highly underserved diseases. We are confident that dry eye patients in Australasia will greatly benefit from the use of NovaTears and our partnership with AFT.” “AFT is dedicated to bringing innovative products to market that make a real difference to people’s health,” said Hartley Atkinson, MD, CEO, AFT. “The addition of NovaTears to our eye care line will be welcomed by doctors and patients alike. It’s a first-in-class, water-free and preservative-free treatment based on Novaliq’s proprietary EyeSol® technology platform. NovaTears supports the lipid layer of the tear film by its ability to quickly spread and be absorbed into the eye. We believe that this feature – combined with its small droplet size – will provide superior benefits to patients with evaporative dry eye disease.” About NovaTears NovaTears, the first product developed and commercialized that incorporates Novaliq’s proprietary EyeSol technology, is an innovative multi-dose, non-aqueous and preservative-free topical eye drop for the lubrication of the ocular surface. The NovaTearsdroplet forms a thin and smooth protecting film supporting the lipid layer in its function to prevent tear evaporation for the relief of dry eye and irritated eye symptoms. NovaTears has been classified as a class Ⅱa medical device and received CE mark approval in Europe in July 2013. Open, prospective, uncontrolled post-market clinical studies NT-001 and NT 002 successfully demonstrated safety and significant improvement in signs and symptoms of dry eye disease and Meibomian gland dysfunction. All results of the study point towards excellent clinical performance, safety and very high convenience and acceptance of NovaTears for patients suffering from hyper-evaporative dry eye. About AFT Pharmaceuticals – AFT founded in 1997 is an Auckland, New Zealand-based pharmaceuticals company operating in Australia, New Zealand and the Pacific Islands. AFT is listed on the Australian [ASX] and New Zealand [NZX] stock exchanges since December 2015 and has significant local sales operations in Australasia together with R&D activities in pain, orphan drugs and medical devices. About Novaliq – Novaliq GmbH, founded in 2004, is a Heidelberg based specialty pharmaceutical company focused on ophthalmology. Its mission is to transform poorly soluble drugs into effective ocular therapeutics for both the front and the back of the eye. Novaliq’s proprietary EyeSol technology enhances the topical bio availability, stability and safety of traditionally insoluble or unstable drugs improving the delivery, efficacy and convenience of treatments for ocular surface diseases including dry eye through preservative free and multi dose formulations. Novaliq’s most advanced product is NovaTears® with CE-marking based on Novaliq’s proprietary EyeSol technology. NovaTears is marketed under the brand name EvoTears® in Europe. More on www.novaliq.com. View source version on businesswire.com: http://www.businesswire.com/news/home/20170320006165/en/ Novaliq Michael O’Rourke, + 1 813-323-1438 Strategic Consultant

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

TLC Therapeutics Patents

TLC Therapeutics has filed 2 patents.

The 3 most popular patent topics include:

  • Dosage forms
  • Drug delivery devices
  • Piperazines
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/6/2020

3/9/2021

Dosage forms, Piperazines, Piperidines, Drug delivery devices, Fluoroarenes

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

2/6/2020

00/00/0000

Grant Date

3/9/2021

00/00/0000

Title

Subscribe to see more

Related Topics

Dosage forms, Piperazines, Piperidines, Drug delivery devices, Fluoroarenes

Subscribe to see more

Status

Grant

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.